dhp1401 + donepezil

**DHP1401 + donepezil** is a combination therapy investigated for the treatment of mild-to-moderate Alzheimer's disease. DHP1401 is a small molecule drug isolated from the seeds of Zizyphus jujuba var. spinosa, with neuroprotective and memory-enhancing effects demonstrated in preclinical models. DHP1401 is believed to modulate several brain targets: AMPA receptor, AMP-activated protein kinase (AMPK), and Mitogen-activated protein kinase (MAPK), enhancing synaptic transmission and memory performance. Donepezil is an acetylcholinesterase inhibitor approved for Alzheimer's disease, acting by increasing levels of acetylcholine in the brain. Clinical trials have assessed the safety and efficacy of DHP1401 administered together with donepezil in patients with Alzheimer's disease, showing improved secondary cognitive endpoints (MMSE, K-TMT-e type B) and some benefit in select subgroups, though primary efficacy endpoints did not reach significance. No significant drug-drug interactions were observed, and the combination was generally well tolerated for up to 24 weeks[1][3][4][6].

Other names

dhp-1401 + donepezildhp 1401 + donepezil